AIM
REGN icon

Anchor Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Anchor Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142K Sell
184
-66
-26% -$50.5K 0.01% 431
2025
Q4 		$193K Hold
250
– – 0.02% 384
2025
Q3 		$141K Hold
250
– – 0.01% 434
2025
Q2 		$131K Sell
250
-946
-79% -$528K 0.01% 434
2025
Q1 		$759K Buy
1,196
+191
+19% +$131K 0.07% 213
2024
Q4 		$716K Buy
1,005
+147
+17% +$123K 0.07% 218
2024
Q3 		$902K Buy
858
+583
+212% +$649K 0.09% 195
2024
Q2 		$289K Sell
275
-1,185
-81% -$1.15M 0.03% 295
2024
Q1 		$1.41M Buy
1,460
+80
+6% +$76.1K 0.15% 149
2023
Q4 		$1.21M Buy
1,380
+181
+15% +$149K 0.14% 154
2023
Q3 		$987K Buy
1,199
+168
+16% +$132K 0.13% 159
2023
Q2 		$741K Buy
1,031
+261
+34% +$201K 0.09% 184
2023
Q1 		$633K Buy
770
+38
+5% +$28.7K 0.09% 208
2022
Q4 		$528K Sell
732
-327
-31% -$241K 0.08% 223
2022
Q3 		$730K Buy
1,059
+149
+16% +$93.8K 0.11% 175
2022
Q2 		$538K Buy
910
+50
+6% +$32.5K 0.08% 212
2022
Q1 		$601K Buy
860
+85
+11% +$53.8K 0.08% 224
2021
Q4 		$489K Buy
775
+182
+31% +$112K 0.06% 251
2021
Q3 		$359K Sell
593
-87
-13% -$54K 0.05% 274
2021
Q2 		$380K Sell
680
-221
-25% -$112K 0.05% 270
2021
Q1 		$426K Buy
901
+826
+1,101% +$402K 0.06% 231
2020
Q4 		$36.2K Buy
75
+35
+88% +$18.9K 0.01% 518
2020
Q3 		$22.4K Buy
+40
New +$24.3K ﹤0.01% 549
2019
Q4 		– Sell
-10
Closed -$2.77K – 843
2019
Q3 		$2.77K Hold
10
– – ﹤0.01% 737
2019
Q2 		$3.13K Sell
10
-25
-71% -$8.32K ﹤0.01% 723
2019
Q1 		$14.4K Buy
35
+25
+250% +$10.3K ﹤0.01% 595
2018
Q4 		$3.73K Hold
10
– – ﹤0.01% 717
2018
Q3 		$4.04K Hold
10
– – ﹤0.01% 739
2018
Q2 		$3.45K Sell
10
-346
-97% -$108K ﹤0.01% 766
2018
Q1 		$123K Buy
356
+324
+1,013% +$113K 0.03% 361
2017
Q4 		$12K Buy
32
+7
+28% +$2.83K ﹤0.01% 617
2017
Q3 		$11.2K Buy
+25
New +$11.9K ﹤0.01% 608

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Anchor Investment Management's REGN Position: Q1 2026 in Review

Anchor Investment Management reduced its Regeneron Pharmaceuticals (REGN) stake by 26% in Q1 2026, selling an estimated $50.5K and leaving 184 shares worth $142K. The position accounts for 0.01% of the portfolio, ranked #431.

Anchor Investment Management first reported a position in REGN in Q3 2017 and has held it in 32 quarters since. The position peaked at $1.41M in Q1 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Anchor Investment Management held 184 shares of Regeneron Pharmaceuticals worth $142K as of Q1 2026.
  • Anchor Investment Management sold 66 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $50.5K.
  • Regeneron Pharmaceuticals made up 0.01% of Anchor Investment Management's portfolio in Q1 2026, its #431 holding.
  • Anchor Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 32 quarters since.
  • Anchor Investment Management's Regeneron Pharmaceuticals position peaked at $1.41M in Q1 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Anchor Investment Management's 13F filing for Q1 2026, filed 1 May 2026.